{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:03:39Z","timestamp":1783569819096,"version":"3.55.0"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2169\/internalmedicine.9035-17","type":"journal-article","created":{"date-parts":[[2017,10,15]],"date-time":"2017-10-15T22:09:45Z","timestamp":1508105385000},"page":"17-23","source":"Crossref","is-referenced-by-count":10,"title":["The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group"],"prefix":"10.2169","volume":"57","author":[{"given":"Noriyoshi","family":"Iriyama","sequence":"first","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hashino","sequence":"additional","affiliation":[{"name":"Health Care Center, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[{"name":"Department of Hematology, Osaka City University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Suwa Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Tokai Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Druker BJ, Guilhot F, O&apos;Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006.","DOI":"10.1056\/NEJMoa062867"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tauchi T, Kizaki M, Okamoto S, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 35: 585-590, 2011.","DOI":"10.1016\/j.leukres.2010.10.027"},{"key":"3","unstructured":"3. Ohnishi K, Nakaseko C, Takeuchi J, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 103: 1071-1078, 2012."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. O&apos;Hare T, Walters DK, Stoffregen EP, et al. <i>In vitro<\/i> activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500-4505, 2005.","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68: 9809-9816, 2008.","DOI":"10.1158\/0008-5472.CAN-08-1008"},{"key":"6","unstructured":"6. Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 91: 869-874, 2016."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270, 2010.","DOI":"10.1056\/NEJMoa1002315"},{"key":"8","unstructured":"8. Hagihara M, Iriyama N, Yoshida C, et al. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. Oncol Rep 36: 2976-2982, 2016."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Murai K, Akagi T, Shimosegawa K, et al. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria. Eur J Haematol 95: 558-565, 2015.","DOI":"10.1111\/ejh.12536"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Inokuchi K, Kumagai T, Matsuki E, et al. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase. J Clin Exp Hematop 54: 197-204, 2014.","DOI":"10.3960\/jslrt.54.197"},{"key":"11","unstructured":"11. Iriyama N, Fujisawa S, Yoshida C, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group. Am J Hematol 90: 282-287, 2015."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kumagai T, Matsuki E, Inokuchi K, et al. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol 99: 41-52, 2014.","DOI":"10.1007\/s12185-013-1483-9"},{"key":"13","unstructured":"13. Iriyama N, Fujisawa S, Yoshida C, et al. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol 90: 819-824, 2015."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23: 1398-1405, 2009.","DOI":"10.1038\/leu.2009.46"},{"key":"15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"15. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94: 135-139, 2009.","journal-title":"Haematologica","ISSN":"https:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Iriyama N, Hatta Y, Takei M. Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes. Cancer Med 5: 3223-3234, 2016.","DOI":"10.1002\/cam4.925"},{"key":"17","unstructured":"17. Schiffer CA, Cortes JE, Hochhaus A, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer 122: 1398-1407, 2016."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yoshida C, Fletcher L, Ohashi K, et al. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol 17: 584-589, 2012.","DOI":"10.1007\/s10147-011-0328-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lopez-Verg\u00e8s S, Milush JM, Pandey S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116: 3865-3874, 2010.","DOI":"10.1182\/blood-2010-04-282301"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kared H, Martelli S, Ng TP, Pender SL, Larbi A. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother 65: 441-452, 2016.","DOI":"10.1007\/s00262-016-1803-z"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Ilander M, Olsson-Str\u00f6mberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31: 1108-1116, 2017.","DOI":"10.1038\/leu.2016.360"},{"key":"22","unstructured":"22. Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2: e528-e535, 2015."},{"key":"23","unstructured":"23. Fujisawa S, Nakamae H, Ogura M, et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol 99: 141-153, 2014."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sakamaki H, Ishizawa K, Taniwaki M, et al. Phase 1\/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 89: 332-341, 2009.","DOI":"10.1007\/s12185-009-0260-2"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Suh KJ, Lee JY, Shin DY, et al. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. Int J Hematol 2017 (Epub ahead of print).","DOI":"10.1007\/s12185-017-2225-1"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 116: 377-386, 2010.","DOI":"10.1002\/cncr.24734"},{"key":"27","unstructured":"27. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol 5: 85-97, 2013."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Miura M. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 38: 645-654, 2015.","DOI":"10.1248\/bpb.b15-00103"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/1\/57_9035-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T17:13:03Z","timestamp":1659633183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/1\/57_9035-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9035-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}